Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19442862 | 1.00 | SAT1 (0.41) | SAT1CYP3A4TSHRCA2ALDH1A1 | |
| SCHEMBL20972798 | 1.00 | SAT1 (0.41) | SAT1CYP3A4TSHRCA2ALDH1A1 | |
| SCHEMBL10067771 | 1.00 | SAT1 (0.41) | SAT1CYP3A4TSHRCA2ALDH1A1 | |
| SCHEMBL10067774 | 0.94 | SAT1 (0.38) | SAT1CYP3A4TSHRCA2 | |
| SCHEMBL10067767 | 0.94 | SAT1 (0.38) | SAT1CYP3A4TSHRCA2 | |
| SCHEMBL12192204 | 0.93 | — | — | |
| SCHEMBL16815000 | 0.93 | SAT1 (0.45) | SAT1CYP3A4TSHRCA2ALDH1A1 | |
| SCHEMBL16815001 | 0.93 | SAT1 (0.45) | SAT1CYP3A4TSHRCA2ALDH1A1 | |
| SCHEMBL16814867 | 0.93 | SAT1 (0.45) | SAT1CYP3A4TSHRCA2ALDH1A1 | |
| SCHEMBL16815008 | 0.93 | SAT1 (0.45) | SAT1CYP3A4TSHRCA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | IKARIA THERAPEUTICS LLC | 2015-01-01 | — | — | US | disclosed |
| US-8871189-B2 | MMP-targeted therapeutic and/or diagnostic nanocarriers | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | MALLINCKRODT LLC (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | SAT1 4304/4885CYP3A4 3450/4885TSHR 3349/4885 |
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | SAT1 4304/4885CYP3A4 3450/4885TSHR 3349/4885 |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | EPHA2, ANXA6, SLC10A1 | SAT1 3514/4885CYP3A4 4339/4885TSHR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.